相关实验视频

Updated: Jun 18, 2026

Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules

Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules

Published on: August 19, 2015

评估PCL/PLA植入物中孟加拉-PVA组合在持续癌症治疗中的疗效

Sara Demartis¹, Camila J Picco², Eneko Larrañeta³

¹Department of Chemical, Physical, Mathematical and Natural Sciences, University of Sassari, Sassari, 07100, Italy.

Drug delivery and translational research

|September 23, 2024

概括

这项研究开发了一个可植入的药物输送系统,使用Rose Bengal (RB) 在3D打印植入物中的聚乙醇 (PVA) 矩阵中. 该系统为90天提供持续的RB释放,改善癌症治疗和患者遵守.

科学领域:

生物材料科学生物材料科学
药物输送系统药物输送系统
癌症治疗癌症治疗

背景情况:

传统的癌症疗法面临的局限性是由于水溶性药物,如孟加拉 (RB) 的频繁的管理需要.
高溶解度和低脂性RB的需要痛苦,重复的管理,阻碍其临床疗效.
需要先进的药物输送系统,使水溶性抗癌剂的持续局部释放成为可能.

研究的目的:

为孟加拉 (RB) 开发和评估一个先进的长期药物输送系统.
创建生物相容,可植入的设备使用孟加拉装载的聚乙烯醇 (PVA) 矩阵在3D打印的聚烯酸 (PCL) 和聚乳酸 (PLA) 中.
从可植入器件中实现局部和持续释放RB,改善治疗结果.

主要方法:

将孟加拉 (RB) 封装到聚乙醇 (PVA) 矩阵中,形成RB@PVA.
将RB@PVA矩阵纳入3D打印的聚烯酸 (PCL) 和聚乳酸 (PLA) 植入物中.
评估RB负载效率,90天内的体外释放动力学,以及PC-3前列腺癌细胞的细胞毒性测定.

主要成果:

该RB@PVA矩阵实现了高的RB负载效率 (77.34 ± 1.53%).
虽然最初的RB从矩阵中释放很快 (在30分钟内完成),但植入物显示持续释放 (90天内75.84±8.75%).
与自由RB (IC50 2.49 μM) 相比,RB@PVA对PC-3细胞的疗效提高 (IC50 1.19 μM),表明有效抑制癌细胞增殖.

结论:

开发的可植入药物输送系统成功地在90天内实现了水溶性药物Rose Bengal的持续释放.
这种创新的系统,将聚合物矩阵集成到可生物降解的植入物中,提供了一种有希望的方法来减少药物管理频率.
这些发现表明,有很大的潜力改善患者的服从性,并将实验性癌症治疗研究转化为实际的临床应用.

关键词:

通过3D打印打印3D打印.癌症癌症癌症癌症植入物植入物是一种植入物.聚乙烯醇的使用方法的孟加拉语的孟加拉语持续的药物释放持续的药物释放

更多相关视频

Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair

Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair

Published on: September 7, 2017

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...